Inhibikase Therapeutics Inc

NASDAQ:IKT   3:59:50 PM EDT
1.88
+0.02 (+1.08%)
Products, Regulatory, Earnings Announcements

Inhibikase Therapeutics Announces Interim Three-Month Results From Chronic Toxicology Studies Of Its Oral C-Abl Kinase Inhibitor

Published: 10/04/2021 12:16 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Announces Interim Three-month Results From Chronic Toxicology Studies of Its Oral C-abl Kinase Inhibitor, Ikt-148009, in Development for Treatment of Parkinson's Disease.
Interim Animal Data Indicate Toxicology Profile Improves With Extended Daily Oral Dosing of Ikt-148009.
Results Support Further Clinical Evaluation of Ikt-148009.
Pending FDA Review, Planned Phase 2a Study in Parkinson's Disease Patients Expected to Initiate in 2022.
Revenue is expected to be $0.2 Million
Adjusted EPS is expected to be -$0.14

Next Quarter Revenue Guidance is expected to be $0.2 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.